Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs ACANYA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.
Treatment of anaerobic bacterial infections (intra-abdominal, skin and skin structure, gynecologic, bone and joint, central nervous system, lower respiratory tract, endocarditis),Treatment of trichomoniasis (symptomatic and asymptomatic),Treatment of bacterial vaginosis,Treatment of amebiasis (intestinal and hepatic),Prophylaxis of postoperative infection in contaminated or potentially contaminated colorectal surgery,Off-label: Management of Clostridium difficile infection, Helicobacter pylori eradication (part of combination therapy), Crohn's disease (perianal fistulas), rosacea (topical)
FDA-approved for the topical treatment of acne vulgaris in patients 12 years and older
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Apply a pea-sized amount to the entire face once daily in the evening, topical.
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Clindamycin: after topical application, terminal half-life is approximately 2-3 hours in serum, but clinical relevance is minimal due to low systemic levels. Benzoyl peroxide metabolites have a half-life of ~1-2 hours. The clinical effect is primarily local with sustained antimicrobial and keratolytic activity.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy-metronidazole (active) and acid metabolites. Enzymes: CYP450 (primarily CYP2A6 and CYP3A4).
Clindamycin is metabolized primarily by the liver via CYP3A4. Benzoyl peroxide is metabolized to benzoic acid and then excreted in urine.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Acanya (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination applied topically. Systemic absorption is minimal. Clindamycin: <0.1% of applied dose excreted renally as parent and metabolites. Benzoyl peroxide: metabolized to benzoic acid, which is conjugated and excreted renally; <5% of applied dose appears in urine. Fecal excretion is negligible.
<20%, primarily to albumin.
Clindamycin: ~60-94% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). Benzoyl peroxide: not significantly bound; its metabolite benzoic acid is ~35% bound to albumin.
0.8-1.2 L/kg; indicates extensive tissue penetration including CNS, bone, and abscesses.
After topical application, systemic concentrations are negligible; Vd not applicable for parent compound. For clindamycin after intravenous administration, Vd is ~0.6-1.2 L/kg. For benzoyl peroxide, dermal penetration is limited to stratum corneum and pilosebaceous units.
Oral: 100% (nearly complete absorption).
Topical bioavailability: <5% for clindamycin (due to extensive metabolism in skin and low systemic absorption); benzoyl peroxide is essentially not absorbed systemically (<2%).
No adjustment required for GFR >10 m L/min. For GFR <10 m L/min: administer every 12 hours. Hemodialysis: administer normal dose after dialysis; no supplemental dose needed. Peritoneal dialysis: administer normal dose every 12 hours.
No dose adjustment required for renal impairment; safety in severe renal impairment not established.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 7.5 mg/kg every 12 hours). Child-Pugh C: use contraindicated or reduce dose to 7.5 mg/kg every 24 hours with close monitoring.
No dose adjustment required for hepatic impairment; use caution in severe hepatic impairment.
Neonates (0-6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 12 hours. Infants/children (>6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Approved for patients aged 12 years and older. For children 12-17 years: apply a pea-sized amount to the entire face once daily.
No specific dose adjustment based solely on age. Monitor renal function and adjust if GFR <10 m L/min. Consider reduced hepatic clearance; use lowest effective dose and monitor for adverse effects.
No specific dose adjustment; use smallest effective amount due to increased risk of skin atrophy in elderly.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Its use should be reserved for conditions described in the indications. Unnecessary use should be avoided.
There is no FDA black box warning for Acanya.
Carcinogenicity risk (animal data; avoid unnecessary use),Seizures and peripheral neuropathy (discontinue if abnormal neurologic signs occur),Hepatic impairment: dose adjustment may be required; caution in severe liver disease,Renal impairment: accumulation of metabolites; monitor for toxicity,Blood dyscrasias: history of or current; monitor CBC with prolonged therapy,Candidiasis: may cause overgrowth; treat appropriately,Disulfiram-like reaction with alcohol: avoid alcohol during and for 48 hours after therapy,Drug interactions: warfarin (increased INR), lithium (increased toxicity), CYP450 inducers/inhibitors,Pregnancy: reserve for serious infections; use in trichomoniasis only if no alternative,Lactation: discontinue breastfeeding or drug, considering importance to mother
Colitis: Clindamycin may cause pseudomembranous colitis; discontinue if diarrhea occurs.,Skin irritation: Benzoyl peroxide may cause allergic contact dermatitis and photosensitivity; avoid excessive sun exposure.,For external use only; avoid contact with eyes and mucous membranes.
Hypersensitivity to metronidazole or other nitroimidazoles,First trimester of pregnancy (for trichomoniasis; relative contraindication),Concurrent use of disulfiram (psychotic reactions possible),Patients with Cockayne syndrome (risk of severe hepatic adverse reactions)
Hypersensitivity to clindamycin, benzoyl peroxide, or any component of the formulation.,History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
No direct food interactions, but alcohol and alcohol-containing foods (e.g., sauces, vinegar, fermented products) must be strictly avoided during therapy and for 48 hours after completion due to risk of disulfiram-like reaction.
No specific food interactions reported. Avoid concurrent use with other topical acne products unless directed.
Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: Generally considered safe for short-term treatment of bacterial vaginosis or trichomoniasis; no evidence of increased major malformations. However, use only if clearly needed.
ACANYA (clindamycin phosphate 1.2% and benzoyl peroxide 5%) is for topical use. Systemic absorption is minimal; however, clindamycin is FDA Pregnancy Category C. Animal studies show no teratogenicity, but no adequate human studies exist. Benzoyl peroxide is Category C with unknown risk. First trimester: theoretical risk from systemic clindamycin if absorbed; second and third trimesters: minimal risk due to low absorption. No reported human teratogenicity for topical use.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Infant serum levels may be up to 20% of maternal levels. Due to potential carcinogenicity in animal studies and concerns for infant gastrointestinal effects, the manufacturer recommends discontinuing breastfeeding during therapy and for 24-48 hours after last dose. Alternative washing and pumping may be considered.
Clindamycin is excreted in human milk after systemic administration; topical application yields negligible systemic levels. M/P ratio not established for topical route. Benzoyl peroxide is not known to be excreted in milk. Risk to infant is low if applied to small areas. Use caution if applied to large areas or broken skin.
Pregnancy may alter metronidazole pharmacokinetics: slightly increased clearance and volume of distribution. No specific dose adjustment is recommended; use standard dosing (e.g., 500 mg IV every 6-8 hours for anaerobic infections). Avoid high doses and prolonged therapy unless essential.
No dosing adjustment required for topical ACANYA in pregnancy. Systemic absorption is low and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety. Use standard dosing: apply once daily to affected areas.
Flagyl IV RTU (metronidazole) is a nitroimidazole antibiotic used for anaerobic infections and protozoal diseases. Avoid alcohol during therapy and for 48 hours after due to disulfiram-like reaction. Infuse slowly over 30-60 minutes to minimize infusion reactions. Monitor for peripheral neuropathy and CNS effects with prolonged use. Use with caution in hepatic impairment; adjust dose in severe liver disease. May cause metallic taste. Do not mix with other drugs in the same IV line. Contraindicated in first trimester of pregnancy unless life-threatening.
ACANYA (clindamycin 1.2% / benzoyl peroxide 2.5%) is a fixed-dose combination gel for acne vulgaris. Apply once daily; avoid excessive application. May bleach hair or colored fabrics. Counsel patients about skin dryness, peeling, and photosensitivity. Consider alternative if significant irritation occurs.
Do not drink alcohol or use products containing alcohol during treatment and for at least 48 hours after the last dose; this can cause severe nausea, vomiting, flushing, and headache.,This medication may cause a metallic taste in the mouth, which is temporary.,If you experience numbness, tingling, or pain in your hands or feet, or any signs of an allergic reaction, contact your healthcare provider immediately.,For IV administration, the infusion site should be monitored for signs of redness, swelling, or pain.,Take the medication exactly as prescribed; do not stop without consulting your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Wash affected area gently before applying a thin layer once daily.,Avoid contact with eyes, mouth, lips, and mucous membranes.,May cause skin dryness, peeling, or redness; use moisturizer if needed.,Benzoyl peroxide can bleach hair or colored fabrics; avoid contact.,Use sunscreen daily as this product increases sun sensitivity.,If severe irritation or allergic reaction occurs, stop use and consult doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL I.V. RTU IN PLASTIC CONTAINER vs ACANYA, answered by our medical review team.
FLAGYL I.V. RTU IN PLASTIC CONTAINER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.. ACANYA is a Topical Antibiotic that works by Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL I.V. RTU IN PLASTIC CONTAINER and ACANYA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL I.V. RTU IN PLASTIC CONTAINER is: Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.. The standard adult dose of ACANYA is: Apply a pea-sized amount to the entire face once daily in the evening, topical.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL I.V. RTU IN PLASTIC CONTAINER and ACANYA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL I.V. RTU IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: General. ACANYA is classified as Category C. ACANYA (clindamycin phosphate 1.2% and benzoyl peroxide 5%) is for topical use. Systemic absorption is minimal; however, clindamycin is FDA Pregnancy Category C. Animal studies sho. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.